Fullerton Fund Management Co Ltd. Has $138.73 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Fullerton Fund Management Co Ltd. increased its position in Boston Scientific Co. (NYSE:BSX) by 52.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,553,156 shares of the medical equipment provider’s stock after acquiring an additional 533,346 shares during the period. Boston Scientific makes up 4.8% of Fullerton Fund Management Co Ltd.’s portfolio, making the stock its 8th biggest position. Fullerton Fund Management Co Ltd. owned approximately 0.11% of Boston Scientific worth $138,728,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Colonial Trust Co SC raised its holdings in shares of Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 260 shares during the last quarter. TFC Financial Management Inc. boosted its position in Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 210 shares during the period. West Oak Capital LLC bought a new position in shares of Boston Scientific in the fourth quarter worth $29,000. Valley National Advisers Inc. increased its holdings in shares of Boston Scientific by 262.4% during the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 286 shares during the period. Finally, Fairway Wealth LLC bought a new stake in shares of Boston Scientific during the fourth quarter valued at about $36,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Down 0.4 %

Shares of Boston Scientific stock opened at $102.87 on Friday. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a 1 year low of $71.88 and a 1 year high of $107.17. The stock has a 50-day moving average price of $98.68 and a 200 day moving average price of $95.93. The company has a market cap of $152.19 billion, a P/E ratio of 82.30, a P/E/G ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to analysts’ expectations of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm’s quarterly revenue was up 20.9% compared to the same quarter last year. During the same period last year, the company posted $0.56 earnings per share. As a group, analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BSX. Wells Fargo & Company increased their target price on shares of Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Raymond James raised their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the company a “strong-buy” rating in a research note on Thursday, February 6th. UBS Group upped their target price on Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. BTIG Research reissued a “buy” rating and issued a $124.00 price objective on shares of Boston Scientific in a research note on Wednesday, April 23rd. Finally, Barclays raised their target price on Boston Scientific from $118.00 to $125.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Twenty-three analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $114.52.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the transaction, the chief executive officer now owns 1,535,706 shares in the company, valued at $157,379,150.88. This represents a 9.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP John Bradley Sorenson sold 4,572 shares of the firm’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the transaction, the executive vice president now owns 18,705 shares in the company, valued at $1,955,420.70. This represents a 19.64 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 300,497 shares of company stock valued at $31,056,815. 0.50% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.